A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 747-754

  Nieves, Wildaliz ^a   Petersen, Hailey ^a   Judy, Barbara M ^b   Blumentritt, Carla A ^b   Russell Lodrigue, Kasi ^c   Roy, Chad J ^a,c   Torres, Alfredo G ^b   Morici, Lisa A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL CAPSULE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BACTERICIDAL ACTIVITY; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; GRAM NEGATIVE SEPSIS; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INFECTION PREVENTION; LETHALITY; MELIOIDOSIS; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; SYSTEMIC DISEASE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; IMMUNOLOGY; SECRETORY VESICLE; SEPSIS; SERUM BACTERICIDAL ACTIVITY; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; BURKHOLDERIA PSEUDOMALLEI; CROSS PROTECTION; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELIOIDOSIS; MICE, INBRED BALB C; SECRETORY VESICLES; SEPSIS; SURVIVAL ANALYSIS;

EID: 84899752262     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00119-14     Document Type: Article

References (50)

1. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N. Engl. J. Med. 367:1035-1044. http://dx.doi.org/10.1056/NEJMra1204699.
2. Currie BJ, Dance DA, Cheng AC. 2008. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S1-S4. http://dx.doi.org/10.1016/S0035-9203(08)70002-6.
3. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NP, Peacock SJ. 2010. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 82:1113-1117. http://dx.doi.org/10.4269/ajtmh.2010.10-0038.
4. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. 2005. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol. 43:970-972. http://dx.doi.org/10.1128/JCM.43.2.970-972. 2005. (Pubitemid 40256075)
5. Currie BJ, Fisher DA, Anstey NM, Jacups SP. 2000. Melioidosis: acute and chronic disease, relapse and re-activation. Trans. R. Soc. Trop. Med. Hyg. 94:301-304. http://dx.doi.org/10.1016/S0035-9203(00)90333-X. (Pubitemid 30406565)
6. Silva EB, Dow SW. 2013. Development of Burkholderia mallei and pseudomallei vaccines. Front. Cell. Infect. Microbiol. 3:10. http://dx.doi.org/10.3389/fcimb.2013.00010.
7. Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day NP, Titball RW. 2012. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl. Trop. Dis. 6:e1488. http://dx.doi.org/10.1371/journal.pntd.0001488.
8. Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW. 2011. Development of vaccines against Burkholderia pseudomallei. Front. Microbiol. 2:198. http://dx.doi.org/10.3389/fmicb.2011.00198.
9. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 4:e900. http://dx.doi.org/10.1371/journal.pntd.0000900.
10. Cheng AC. 2010. Melioidosis: advances in diagnosis and treatment. Curr. Opin. Infect. Dis. 23:554-559. http://dx.doi.org/10.1097/QCO.0b013e32833fb88c.
11. Van Zandt KE, Tuanyok A, Keim PS, Warren RL, Gelhaus HC. 2012. An objective approach for Burkholderia pseudomallei strain selection as challenge material for medical countermeasures efficacy testing. Front. Cell. Infect. Microbiol. 2:120. http://dx.doi.org/10.3389/fcimb.2012.00120.
12. Holden MT, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PC, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U. S. A. 101:14240-14245. http://dx.doi.org/10.1073/pnas.0403302101. (Pubitemid 39305059)
13. Limmathurotsakul D, Chaowagul W, Chierakul W, Stepniewska K, Maharjan B, Wuthiekanun V, White NJ, Day NP, Peacock SJ. 2006. Risk factors for recurrent melioidosis in northeast Thailand. Clin. Infect. Dis. 43:979-986. http://dx.doi.org/10.1086/507632. (Pubitemid 44631096)
14. Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, Aucoin DP, McLachlan JB, Roy CJ, Morici LA. 2011. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29:8381-8389. http://dx.doi.org/10.1016/j.vaccine.2011.08.058.
15. Kulp A, Kuehn MJ. 2010. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 64:163-184. http://dx.doi.org/10.1146/annurev.micro.091208.073413.
16. Deatherage BL, Cookson BT. 2012. Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. Infect. Immun. 80:1948-1957. http://dx.doi.org/10.1128/IAI.06014-11.
17. Nieves W, Heang J, Asakrah S, Honer zu Bentrup K, Roy CJ, Morici LA. 2010. Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization. PLoS One 5:e14361. http://dx.doi.org/ 10.1371/journal.pone.0014361.
18. Qazi O, Rani M, Gnanam AJ, Cullen TW, Stead CM, Kensing H, McCaul K, Ngugi S, Prior JL, Lipka A, Nagy JM, Gregory CW, Judy BM, Harding SV, Titball RW, Sidhu SS, Trent MS, Kitto GB, Torres A, Estes DM, Iverson B, Georgiou G, Brown KA. 2011. Development of reagents and assays for the detection of pathogenic Burkholderia species. Faraday Discuss. 149:23-36. http://dx.doi.org/10.1039/c005422b.
19. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M. 1995. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 63:3348-3352.
20. AuCoin DP, Reed DE, Marlenee NL, Bowen RA, Thorkildson P, Judy BM, Torres AG, Kozel TR. 2012. Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS One 7:e35386. http://dx.doi.org/10.1371/journal.pone.0035386.
21. Warawa JM. 2010. Evaluation of surrogate animal models of melioidosis. Front. Microbiol. 1:141. http://dx.doi.org/10.3389/fmicb.2010.00141.
22. Bishop AL, Schild S, Patimalla B, Klein B, Camilli A. 2010. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect. Immun. 78:4402-4420. http://dx.doi.org/10.1128/IAI.00398-10.
23. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl 2):B3-B12. http://dx.doi.org/10.1016/j.vaccine.2009.04.071.
24. DuBois AB, Freytag LC, Clements JD. 2007. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 25:4747-4754. http://dx.doi.org/10.1016/j.vaccine.2007.03.048. (Pubitemid 46755451)
25. Reckseidler-Zenteno SL, DeVinney R, Woods DE. 2005. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect. Immun. 73:1106-1115. http://dx.doi.org/10.1128/IAI.73.2.1106-1115.2005. (Pubitemid 40165771)
26. Sarkar-Tyson M, Smither SJ, Harding SV, Atkins TP, Titball RW. 2009. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine 27:4447-4451. http://dx.doi.org/10.1016/j.vaccine.2009.05.040.
27. Rodrigues F, Sarkar-Tyson M, Harding SV, Sim SH, Chua HH, Lin CH, Han X, Karuturi RK, Sung K, Yu K, Chen W, Atkins TP, Titball RW, Tan P. 2006. Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J. Bacteriol. 188:8178-8188. http://dx.doi.org/10.1128/JB.01006-06. (Pubitemid 44845689)
28. Sim SH, Yu Y, Lin CH, Karuturi RK, Wuthiekanun V, Tuanyok A, Chua HH, Ong C, Paramalingam SS, Tan G, Tang L, Lau G, Ooi EE, Woods D, Feil E, Peacock SJ, Tan P. 2008. The core and accessory genomes of Burkholderia pseudomallei: implications for human melioidosis. PLoS Pathog. 4:e1000178. http://dx.doi.org/10.1371/journal.ppat.1000178.
29. Anuntagool N, Wuthiekanun V, White NJ, Currie BJ, Sermswan RW, Wongratanacheewin S, Taweechaisupapong S, Chaiyaroj SC, Sirisinha S. 2006. Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. Am. J. Trop. Med. Hyg. 74:348-352. (Pubitemid 46774353)
30. Tuanyok A, Stone JK, Mayo M, Kaestli M, Gruendike J, Georgia S, Warrington S, Mullins T, Allender CJ, Wagner DM, Chantratita N, Peacock SJ, Currie BJ, Keim P. 2012. The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl. Trop. Dis. 6:e1453. http://dx.doi.org/10.1371/journal.pntd.0001453.
31. Burtnick MN, Heiss C, Roberts RA, Schweizer HP, Azadi P, Brett PJ. 2012. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front. Cell. Infect. Microbiol. 2:108. http://dx.doi.org/10.3389/fcimb.2012.00108.
32. Sim BM, Chantratita N, Ooi WF, Nandi T, Tewhey R, Wuthiekanun V, Thaipadungpanit J, Tumapa S, Ariyaratne P, Sung WK, Sem XH, Chua HH, Ramnarayanan K, Lin CH, Liu Y, Feil EJ, Glass MB, Tan G, Peacock SJ, Tan P. 2010. Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol. 11:R89. http://dx.doi.org/10. 1186/gb-2010-11-8-r89.
33. Zou N, Tsai S, Feng SH, Newsome T, Kim HY, Li B, Zhang S, Lo SC. 2008. Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse MAbs. Hybridoma (Larchmt.) 27:231-240. http://dx.doi.org/10.1089/hyb.2008.0012.
34. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527. (Pubitemid 29200936)
35. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. 2007. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 25:3075-3079. http://dx.doi.org/10. 1016/j.vaccine.2007.01.023. (Pubitemid 46482737)
36. van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J. 1996. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64:2745-2751. (Pubitemid 26226842)
37. Chenthamarakshan V, Kumutha MV, Vadivelu J, Puthucheary SD. 2001. Distribution of immunoglobulin classes and IgG subclasses against a culture filtrate antigen of Burkholderia pseudomallei in melioidosis patients. J. Med. Microbiol. 50:55-61. (Pubitemid 32042807)
38. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, Chaowagul W, Bryan LE. 1997. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 65:3648-3653. (Pubitemid 27398120)
39. Rolim DB, Vilar DC, de Goes Cavalcanti LP, Freitas LB, Inglis TJ, Nobre Rodrigues JL, Nagao-Dias AT. 2011. Burkholderia pseudomallei antibodies in individuals living in endemic regions in northeastern Brazil. Am. J. Trop. Med. Hyg. 84:302-305. http://dx.doi.org/10.4269/ajtmh.2011.10-0220.
40. Zhang S, Feng SH, Li B, Kim HY, Rodriguez J, Tsai S, Lo SC. 2011. In vitro and in vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin. Vaccine Immunol. 18:825-834. http://dx.doi.org/10.1128/CVI.00533-10.
41. Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW. 2013. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect. Immun. 81:4626-4634. http://dx.doi.org/10.1128/IAI.00915-13.
42. Healey GD, Elvin SJ, Morton M, Williamson ED. 2005. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect. Immun. 73:5945-5951. http://dx.doi.org/10.1128/IAI.73.9.5945-5951.2005. (Pubitemid 41193033)
43. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181:713-721. http://dx.doi.org/10.1084/jem.181.2.713.
44. Allwood EM, Devenish RJ, Prescott M, Adler B, Boyce JD. 2011. Strategies for intracellular survival of Burkholderia pseudomallei. Front. Microbiol. 2:170. http://dx.doi.org/10.3389/fmicb.2011.00170.
45. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, Putnam D. 2010. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:3099-3104. http://dx.doi.org/10.1073/pnas.0805532107.
46. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. 2007. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect. Immun. 75:4173-4180. http://dx.doi.org/10.1128/IAI.00404- 07. (Pubitemid 47206316)
47. Stevens MP, Haque A, Atkins T, Hill J, Wood MW, Easton A, Nelson M, Underwood-Fowler C, Titball RW, Bancroft GJ, Galyov EE. 2004. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150:2669-2676. http://dx.doi.org/10.1099/mic.0.27146-0. (Pubitemid 39173270)
48. Tippayawat P, Pinsiri M, Rinchai D, Riyapa D, Romphruk A, Gan YH, Houghton RL, Felgner PL, Titball RW, Stevens MP, Galyov EE, Bancroft GJ, Lertmemongkolchai G. 2011. Burkholderia pseudomallei proteins presented by monocyte-derived dendritic cells stimulate human memory T cells in vitro. Infect. Immun. 79:305-313. http://dx.doi.org/10.1128/IAI.00803-10.
49. Muralinath M, Kuehn MJ, Roland KL, Curtiss R, III. 2011. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect. Immun. 79:887-894. http://dx.doi.org/10. 1128/IAI.00950-10.
50. Koeberling O, Delany I, Granoff DM. 2011. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin. Vaccine Immunol. 18:736-742. http://dx.doi.org/10.1128/CVI. 00542-10.